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Abstract: Dendritic cells (DCs) play a prime role in the activation and control of the immune 
system and have promising potential in the treatment of cancer, viral infection, autoimmune 
diseases and transplantation rejection. DCs can be generated ex vivo from human monocytes by 
the use of growth factors or during transendothelial migration. Many studies have generated DCs 
under static, “no flow” conditions. However, such studies do not mimic the “flow” occurring in 
the capillaries. The objective of this study was to see if we could generate functional DCs within 
a novel bioreactor system under flow conditions. A HUVEC monolayer was grown on a porous 
membrane and added it to a bioreactor at 0.4 mL/min. Inflammation was mimicked by adding 
TNF-α to the system for 48 h. Cell morphology, viability, CAM expression and MCP-1 were 
measured. CFSE-labeled monocytes were added above the flow path. Monocytes were analyzed 
for location based on fluorescent intensity and migration markers. Finally, we looked at the 
differentiation of monocytes into DCs by looking at common DC markers. To test for 
functionality, we performed a mixed leukocyte reaction (MLR) for seven days and measured 
proliferation and activation of T-cells.  
HUVECs maintained a compact network after 72 h. Cell viability with and without TNF-α was 
78% and 82%, respectively. Increased VCAM-1 expression (37%) and MCP-1 (6x) act as 
inflammatory responses to send signals for recruitment of leukocytes. Increased monocyte 
migration through the stimulated endothelium could be due loose HUVEC junctions. All 
migration marker expression was downregulated in a stimulated system, possibly due to 
monocyte shifting away from lineage or differentiation into DCs. DCs from the bioreactor had 
no morphological differences when compared to static culture. DCs attached to the endothelium 
expressed 80% CD206, possibly playing a role in their attachment to the endothelium. DCs after 
culture expressed CD86 and after adding maturation cytokines, bioreactor and static DCs 
matured as indicated by CD83 expression (72% and 84.9%, respectively). DCs from the 
bioreactor proliferated activated T-cells more than static DCs as indicated by MFI. Overall, the 
system was able to generate functional DCs that promoted better T-cell proliferation than 
traditional methods.  
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Chapter I 
 
Introduction 
 
The immune system is the body’s defense mechanism against viral infections, diseases and 
foreign pathogens. It can play a key role in curing cancer, transplantation rejection, and 
autoimmune diseases by identifying and eliminating pathogens while distinguishing healthy cells 
from one’s own body. Dendritic cells (DCs) are one of the key components of the innate immune 
response. Howard et al describe DCs as the one control point of the immune system [1]. DCs are 
initiators and modulators of the immune response by efficiently stimulating T and B cells [2]. 
Just how important are DCs for T-cells during an immune response? T-cells have to be able 
recognize peptides located on infected cells at frequencies of 1/100,000 or less [2]. DCs, located 
in majority of tissues, can capture and process antigens which will then be displayed on their 
surface in large quantities. These mobile cells can then migrate into tissue and present the 
specific antigen to T-cells, thus activating and beginning the defense mechanism. DCs are able to 
stimulate proliferation of T-cells almost 100x more than macrophages or other lymphoid 
subpopulations [3].  
DC population within blood is relatively low, with the percentage of total cells around 1-2%. 
Currently in research settings, DCs are typically generated in static cultures from monocytes by 
the use of cytokines and growth factors, such as granular-macrophage colony-stimulating factor 
(GM-CSF) and interleukin (IL)-4, as first discovered by Sallusto and Lanzavecchia [4]. They 
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were able to generate immature DCs, which are better at capturing soluble antigens. After 
addition of tumor necrosis factor (TNF)-α, DCs generated using this method have a better ability 
to present and stimulate allogenic T-cells than previous CD34+ precursor cells. Randolph et al 
showed also that monocytes could differentiate into DCs after migration across an endothelium 
layer without the presence of additional cytokines [5]. They also showed DCs predominantly 
reverse transmigrated, while macrophages did not. Endothelial cells (ECs) line every blood 
vessel and are important for tissue growth and repair. The ability to migrate back and forth 
across a tissue layer is another important feature of DCs. Shukla followed up on this and showed 
that the number of monocytes that differentiated into immature DCs across an EC layer increased 
as glucose concentration increased on a 3D collagen matrix tissue model [6]. 
Although good representations of cell behavior in response to certain variations, these 3D 
vascular constructs studied previously still lack many physiological effects taking place in vivo 
[5, 6]. Bioreactors have emerged as a way to combine the dynamic effects similar to in vivo 
conditions with traditional static cell cultures. Bioreactors have been shown to increase cell 
viability, function and cell alignment more resemblant of how they are in the body [7, 8]. DCs 
have been generated in a dynamic system but they failed to show significant increase in 
functionality when compared to static DCs due possibly to it being microgravity system [9]. 
Previous works with vascular constructs were done in batch systems, by putting cells in and 
removing all at once after culture. Although effective, this process leads to cell loss and longer 
times in between experiments. A continuous process could reduce both of those and generate 
more cells at the same time. To the best of our knowledge, there have been no studies that have 
added monocytes above the flow path of a vascular tissue construct in order to generate DCs ex 
vivo. This method leads to cells migrating beneath the vascular construct while still having the 
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ability to add more precursor cells above simultaneously. Because of this, we propose a new 
system that hopefully is able to generate functional DCs similar to those grown in traditional 
static cultures.  
Problem Statement 
 
The overall goal is to develop a novel continuous system that can produce functional DCs by 
constructing a tissue-engineered construct within a bioreactor. The design will be based on 
previous works that will be co-culturing endothelial cells with monocytes except along with 
studying the migration, we will also look to analyze the functionality of DCs generated from 
monocytes [5, 6]. The long-term goal is to be able to develop a patient specific DC-based 
therapeutic that could be used to treat a variety of diseases. This research is the initial step 
toward obtaining that goal. The hypothesis is that DCs generated in a novel vascular construct 
will be better stimulators for proliferation of T-cells than traditional methods. This research was 
done in three parts to establish a system for generation of DCs.  
a. Characterize the 3D vascular tissue construct within a bioreactor with flow conditions. 
The first objective was to characterize a vascular tissue construct after introducing it to a 
bioreactor under flow conditions. After 72 h, we analyzed cell morphology using fluorescent 
microscopy. We measured cell viability and common cellular adhesion molecules (CAMs) by 
using of flow cytometry. We also looked at release of a soluble protein related to recruitment of 
monocytes. An inflammatory stimulus was added for some studies to investigate the effects on 
the vascular tissue construct.  
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b. Characterize monocyte migration within the bioreactor. 
For this aim, we characterized monocyte migration within various regions in the bioreactor. 
After the vascular tissue construct had been added for 24 h with and without an inflammatory 
stimulus, monocytes labeled with a fluorescent probe were added to the system for the final 48 h. 
Monocyte location was measured by fluorescent intensity using a standard curve. Monocytes 
were also analyzed by flow cytometry for surface protein expression related to migration.  
c. Characterize DCs generated in a bioreactor system 
DCs have been studied extensively on their role in immune response and how different 
generation techniques affect their functionality. Most studies generate DCs from monocytes by 
using certain growth factors, such as granulocyte-macrophage colony-stimulating factor (GM-
CSF) and IL-4 in 2D culture system. Here, we added monocytes to the bioreactor with a vascular 
construct and studied their differentiation into DCs without additional cytokines. In order to test 
for DCs differentiated in the bioreactor system, we used flow cytometry to analyze key DC 
surface markers. Once generated, cells were tested for functionality using a mixed leukocyte 
reaction (MLR) with autologous T-cells. We compared how loading DCs with an antigen 
affected their ability to stimulate proliferation and activation of T-cells.   
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Chapter II 
 
Background 
 
 
 
2.1 Inflammatory Response 
 
The human body is constantly fighting millions of toxic and pathogenic microbes that enter its 
systems daily. The defense mechanism utilized to combat foreign and dangerous microbes is the 
immune system. Failure to eliminate any inflammation can cause severe tissue damage. An 
immune response happens in four common steps: surface receptors detect foreign stimuli; 
inflammatory pathways are activated; inflammatory stimuli are released; and inflammatory 
response cells are recruited. Toll-like receptors on macrophages detect when a foreign pathogen 
is present and release inflammatory chemokines and cytokines such as tumor-necrosis factor 
(TNF)-α and interleukin (IL)-6 to indicate where localization of neutrophils and monocytes 
should be [10, 11]. Inflammatory response cells then work together to eliminate the pathogen, 
with monocytes differentiating into DCs and macrophages; macrophages undergoing 
phagocytosis; DCs stimulating T-cell and B-cell response and mast cells releasing inflammatory 
mediators. When cells are not able to limit or suppress the inflammation, inflammation is then 
considered to be chronic. This could be due to a number of factors like chronic infections, failing 
to regulate T-cell response, and autoimmune cells attacking healthy host cells [10, 11]. 
Resolution of inflammation begins when pro-resolving mediators such as nuclear factor kappa B 
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(NF-κB) are turned on. Expression of NF-κB results in downregulation of TNF-α, decreasing the 
recruitment of neutrophils and other leukocytes to the site of inflammation [12]. Neutrophils at 
the site of inflammation begin to undergo apoptosis and are cleared by macrophages, therefore 
returning the tissue to homeostasis.  
 
2.2 Blood vessels 
 
The ECs are the so called “gate keepers”, regulating cell, nutrient, and waste passage to and from 
the blood. Complications with growth or maintenance can lead to a stroke, inflammatory 
disorders, blinding eye disease and pulmonary hypertension [13]. White blood cells continually 
will circulate in the blood, looking for any infection or damage done in the body. Once an 
abnormality is discovered, vascular cells release cytokines to recruit various leukocytes to that 
location. These cytokines can then alter cells receptors or adhesion molecules of ECs lining the 
blood vessels which in turn affect leukocytes ability to attach, roll and then transmigrate through 
endothelium junctions. The vascular endothelium can also express lymphocyte costimulatory 
molecules which can stimulate proliferation of T-cells [14].  
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Figure 1. Structure of blood vessel. Taken from https://courses.lumenlearning.com/boundless-
ap/chapter/blood-vessel-structure-and-function/ 
 
2.3 Cells 
 
2.3.1 Endothelial Cells 
 
In an adult human, ECs account for approximately 6 x 1013 cells and cover up to 7 m2 of surface 
area [15]. In research, ECs have been used to study inflammation, atherosclerosis, diabetes, and 
study the effect of pharmaceuticals and their ability to penetrate the blood-tissue barrier[16]. 
When ECs are under normal conditions, they do not interact with leukocytes due to suppressing 
interactive proteins such as P-selectin and chemokines [17, 18]. During an acute inflammation, 
ECs have two types of activation methods. Type I activation consist mainly of elevated release of 
Ca2+ from endoplasmic reticulum storage [18]. Release of more Ca2+ leads activation of the 
myosin-light-chain kinase (MLCK), producing myosin light chain (MLC) which cause ECs to 
begin contracting to open up junctions between adjacent ECs [19]. The loose EC membranes 
allow for leukocytes to pass through the endothelium by the interaction of CD31 (PECAM-1) 
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and CD99 on ECs, which are important for transmigration [20]. Type II activation occurs when 
the inflammation is more damaging. Tumor-necrosis factor (TNF)-α is released from activated 
leukocytes and binds to domains of TNF receptor 1 on ECs [18, 21]. This activation then leads to 
looser junctions and increased leukocyte recruitment to activation site. Increased amounts of 
TNF-α bound to ECs has also shown to increase the expression of CD54 (ICAM-1) and CD106 
(VCAM-1) as well as an increase in secretion of monocyte chemoattractant protein (MCP-1) and 
IL-8 [16, 18]. TNF-α has also been shown to trigger cell death after exposure for a lengthy 
period of time [18].  
2.3.2 Monocytes 
 
Monocytes are one of the most pivotal cells part of the immune system. They play a major role 
in defending the body against infectious diseases and can differentiate into macrophages or DCs 
[22]. Monocytes are characterized by their bean shape nuclei and expression of CD11b, CD11c 
and CD14 [23]. Monocytes account for approximately 10% of leukocytes in blood originating 
out of bone marrow [24]. From there, monocytes migrate into the blood where they patrol the 
vascular system and eventually migrate into tissues such as spleen, liver and lungs. In humans, 
monocytes are characterized by three subsets of their phenotypic expression: CD14+CD16- 
(classical), CD14+CD16+(intermediate), CD14dimCD16+ (non-classical) [24]. Classical 
monocytes are CCR2+, produce high levels of IL-10 and respond to toll-like receptors (TLR) 2 
and 4 ligands while non-classical monocytes lack CCR2 and respond to viral stimuli [25, 26]. 
Classical monocytes major role phagocytosis and express genes involved in angiogenesis, wound 
healing and coagulation [26].  
When an inflammation occurs, monocytes undergo a change to either DCs or macrophages 
depending on cytokines and transcription factors present. For in vitro studies, culturing 
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monocytes in GM-CSF and IL-4 cause monocytes to favor differentiation into DCs [27]. For 
macrophages, culturing monocytes in M-CSF or IL-32 has sufficed to generate macrophages 
over DCs [28].  
2.3.3 Dendritic Cells 
 
DCs are one of the most potent immune response cells part of the immune response. They have 
been known to play a role in many diseases such as asthma, cancer, atherosclerosis and diabetes 
[11]. DCs are considered the best antigen presenting cell (APC) able to stimulate T-cells [1]. 
DCs originate from myeloid or lymphoid progenitors and can be found in a multitude of 
locations throughout the body such as blood, lungs, liver, spleen, and intestine [29, 30]. Under 
light microscope, DCs are similar to monocytes in morphology with the exception that they have 
thin, long dendrites. From here, DCs are classified in many different ways based on their 
expression of surface molecules. Migratory conventional DCs develop out of peripheral tissues 
and either express CD11b or CD103 [31]. Lymphoid conventional DCs express CD4 and CD8α 
and play a role in priming cytotoxic CD8+ T-cell responses [31]. Blood monocytes have been 
shown to differentiate into DCs under inflammatory conditions and can originate from all three 
types of monocytes. Monocyte derived DCs depend on GM-CSF in vivo [32]. For in vitro 
culturing of monocytes to generate DCs, GM-CSF combined with IL-4 have shown great success 
at generating DCs that will express CD1c and CD206 (MMR) [4, 27, 33].  
Monocyte derived DCs can exist in either an immature or mature form. Having mature DCs is 
important as the most potent antigen presentation will occur only if they are in their maturation 
state. Immature DCs lead to that potent antigen presentation by capturing antigens via 
phagocytosis, micropinocytosis, and mediate adsorptive endocytosis via MMR receptor [2]. 
Antigens are processed in MHC class II compartments to be stored inside the cell. After certain 
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signals such as bacteria or cytokines like IL-1, GM-CSF or TNF-α, the antigens will be sent to 
the surface of the DC and be considered mature and activated [2]. Mature DCs will express very 
high levels of CD40, CD80, CD83 and CD86 and lack the CD14 marker that is found on 
monocytes and some immature DCs [34, 35]. With the antigen present on DC surface, T-cell 
receptors make contact with the DC via CD28 receptor [36]. After roughly 2 h of interaction, T-
cells can begin to proliferate and upregulate their activation surface markers such as CD69 and 
CD25 [36, 37]. T-cells communicate back to DCs by triggering DCs with TNF-related activation 
cytokines which increases DC stimulatory capacity and prolongs their lifecycles [38].  
2.3.3.1 2D Generation of DCs 
 
Numerous studies have generated DCs from monocytes using cytokines [4, 33, 39]. In general, 
using a combination of GM-CSF and IL-4 generates immature DCs in about 7-10 days. GM-CSF 
has been shown to increase viability and function of DCs generated and is key to forming DCs 
over macrophages [40]. To fully mature DCs, the addition of TNF-α is typically added for 24-48 
h. Using only TNF-α does push DCs toward maturation but mature DCs generated lack the 
ability to secrete IL-12 and IFN-γ, which are both involved in activation of T-cells [41]. Using a 
cocktail of various cytokines such as IL-1β, IL-6, PGE2 along with TNF-α has been shown to 
increase the maturity and functionality of DCs generated statically [35, 41, 42].  
2.3.3.2 3D Generation of DCs 
 
By creating a 3D complex, it gives a more representative system than that of 2D. Randolph et al 
looked into the migration of monocytes in a 3D vascular tissue construct [5]. They found that 
monocytes rapidly (48 h) differentiated into DCs after exposure to an endothelium layer within 
their vascular tissue construct. Their work also showed that reverse migrated cells, that later were 
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stimulated with particles, were shown to be predominantly DCs compared to those that remained 
in the subendothelial matrix which were macrophages. Shukla further studied the effects of 
inflammation on monocyte differentiation in a vascular tissue construct [6]. He displayed that 
glucose acts as a proinflammatory stimulus on endothelial cells. When an inflamed endothelium 
was present, cells that had reverse transmigrated across the endothelium were monocyte derived 
immature DCs rather than other leukocytes.  
2.4 Bioreactors 
 
Bioreactors are defined as an apparatus in which biological reactions or processes are carried out. 
Research in cartilage, bone, vascular, skin and nervous tissue have all incorporated bioreactors to 
study varying effects on those cell types [43]. Outside of tissue engineering, bioreactors are used 
in a wide range of applications such as fermentation, waste water treatment and food processing. 
In cell cultures, bioreactors have been used to add a dynamic feature to culturing of cells to better 
mimic what is taking place in vivo. The reason bioreactors are so useful is because one can 
customize the design and control biochemical and mechanical stimuli in a controlled 
environment. This mechanical stimuli directs cellular activity and promotes proper morphology 
similar to in vivo [44]. Having this dynamic feature encourages cells to form their extracellular 
matrix in a shorter time span than if they were grown under static conditions [43]. Mechanical 
stimuli has also been shown to effect protein expression and cell proliferation in positive ways 
[45]. 
Another reason bioreactors are favored over static culture systems is due to them having better 
mass exchange of nutrients and their ability to remove cell waste while culturing. Cell size and 
proliferation increase within a culture requires a better mass transfer to ensure all cell layers 
within a system receive adequate nutrients. It has been shown in previous studies that under 
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static conditions, glycosaminoglycan (GAG) deposits by chondrocytes was poor after roughly 
400 um from the outer surface [44]. When chondrocytes were cultured in a spinner flask 
bioreactor, GAG deposits were able to accumulate in the central part of the construct [44].  
2.5 Current Vascular Bioreactors 
 
2.5.1 Rotating Wall  
Developed by NASA, rotating wall bioreactors (RWB) create a low-shear laminar flow, high 
mass transfer environment which cells free-fall as they rotate during culture. These bioreactors 
work by rotating the vessel horizontally with the inner chamber containing a central porous 
membrane and annular space submerged in medium. The medium is recirculated between the 
central cell culture space to the peripheral cell free space to allow for maximum mass transfer of 
nutrients [46]. The cells within RWB form denser tissues but are successful at sustaining 
viability due to a well-mixed medium that facilitated waste disposal and nutrient transfer [47]. 
Sanford et al. showed that ECs grown in RWB could be cultured for 30 days and form multilayer 
tissue like structures without any changes in morphology or function [47]. They also noticed that 
having ECs cultured in RWB had tighter junctions similar to brain capillaries in vivo.    
Dermenoudis and Missirlis RWB had ECs elongate and form spirals due to mechanical stimuli 
experienced ECs [48].  These spiral formations could be ECs gravitating toward formation of a 
vascular network. Unfortunately, RWB are not good representations of in vivo conditions.  
2.5.2 Perfusion  
Perfusion bioreactors offer a more similar simulation of how flow of fluid acts on cells. Fluid is 
pumped over the cell area either with laminar or pulsatile flow in a closed circuit loop. Geometry 
of the cell growth area is up to the researcher as one can change the scaffold shape dependent on 
need or interest. To optimize the system, researchers have computationally modeled their 
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perfusion bioreactor using various programs prior to experiments [49-51]. By doing this, 
researchers are able to better understand the actual flow the cell layer is experiencing. One key 
difference between perfusion and RWB is perfusion adds a pressure factor that cells will 
experience. Various pressure differences has been shown to effect cell attachment and 
proliferation [50, 51]. Many studies have shown that perfusion bioreactors routinely promote cell 
proliferation, uniform distribution of cells and increase in expression of key surface markers [49, 
52, 53]. Perfusion bioreactors are also able to successfully provide nutrients to all cells and 
remove cell waste due to the constant circulation of media. 
2.5.3 Parallel Plate 
Parallel plate bioreactors are similar to perfusion bioreactors, where media is constantly flowing 
over the cell layer to create fluid shear stress except the cell layer is slightly below the flow path. 
Parallel plate bioreactors ideally are set up to have laminar flow over cells and the shear stress 
that ECs are experiencing are matched to be similar to blood vessels [54]. Parallel plate 
bioreactors are common for studying leukocytes through endothelium due to easiness to make 
and ability to observe cells during experiments. Many factors can be altered to optimize the 
system including channel height and volumetric flow rate. Khismatullin and Truskey noticed that 
the channel height effects the leukocyte adhesion, observing that having a large distance between 
flow path and endothelium reduces the adhesion strength even at similar in vivo shear stress [54]. 
With flow, Luscinskas et al. found that monocyte adhesion to activated ECs increased even at 
higher than usual shear stress [55]. Monocytes and other white blood cells were studied in a 
parallel plate bioreactor to see the effect of disturbed flow. Researchers found that monocytes 
migrated more in the reattachment area of the flow region as well as show that ICAM-1 plays a 
significant role in the migration of cells [56].  
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Chapter III 
 
Materials and Methods 
 
3.1 Design and Fabrication of Bioreactor 
 
The key consideration with the bioreactor was to incorporate the addition of the vascular tissue 
construct. By being able to add the vascular tissue construct, cells were able to attach and reach 
confluency before being exposed to dynamic conditions. This design is based on previous work 
by Fahlenkamp and Shukla which used transwells in plates [6, 57]. The transwells were able to 
separate the samples into 2 chambers, with cells on a membrane used to divide the two similar to 
this bioreactor. The bioreactor was constructed out of Polyether Ether Ketone (PEEK) and made 
in-house. PEEK has an aromatic molecular backbone with ether and ketone functional groups 
between the aryl rings and has shown to be great for biocompatibility both in vivo and in vitro 
[58, 59]. Figure 2A shows a schematic of the bioreactor and Figure 2D shows the complete set-
up of the bioreactor for culture. Each well (six total) has a bottom and top chamber. Six wells 
were chosen so that simultaneous experiments could be run in parallel. The top chamber 
(diameter = 15.9 mm; depth = 13.4 mm) has one inlet and exit (diameter = 2.4 mm) where media 
flows in and out of the well. The bottom chamber (diameter = 9.0 mm) is closed. Luer locks with 
barbed fittings were attached to each bioreactor well to allow for tubing connection. Tubing 
(1.59 cm ID, Masterflex; Gelsenkirchen, Germany) was attached to each barbed connector and 
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then connected to Masterflex L/S Digital drive pump (Cat. #: SI-07522-20) with multichannel 
pump head attached (Masterflex, Item#: HV-07534-08); thus creating a closed, recycle system. 
The pump was calibrated following instructions from manufacturer prior to use. A lid was placed 
on top of the bioreactor to help prevent contamination but allowed for gas exchange to still take 
place. Bioreactor, lid, fittings and tubing were autoclaved to sterilize prior to use. Pump was 
sterilized by UV radiation for 20 minutes prior to use. To sterilize in between experiments, 10% 
bleach was passed through the system for 10 min followed by 2-20 min rinses with water. After 
three experiments, the entire system was broken down, cleaned and autoclaved before starting 
another experiment. 
Optimization of the flow rate was determined with the help of computational fluid dynamics 
(CFD). Reviewing previous literature, we wanted to select a flow rate at which cells would 
experience a shear force but not too much that would cause cell death or detachment from the 
ring. We tried 0.3, 0.4 and 0.5 mL/min flow rates. After experimenting, 0.4 mL/min showed to 
have the greatest viability on cells and most cell proliferation. For all experiments, 0.4 mL/min 
was used as the desired flow rate.  
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Figure 2. Vascular Bioreactor. (A) Schematic of vascular bioreactor (measurements are in 
inches). (B) Female luer locks were attached to the bioreactor plate. (C) Male luer locks were 
connected to the female. For bottom chamber, closed cap pieces were connected. For top 
chamber, barbed pieces were attached so that tubing could be connected from the pump to the 
bioreactor. All pieces were then placed in the autoclave to sterilize. (D) Complete bioreactor 
system set up. After sterilization, connectors were tightened and tubing was connected from the 
A 
B 
C 
D 
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reactor to the pump. Rings with cells were placed in each well insert followed by the flow rate 
being set to 0.4 mL/min.  
 
3.2 Design and Fabrication of Rings 
 
Rings were constructed out of the same material as bioreactor and made in-house. To create a 
surface for cell growth, porous polycarbonate track etch (PCTE) membranes (pore size = 12 µm, 
0.52 cm2; Sterlitech, Kent, WA) were placed in the center of inner rings (ID x OD = 8 x 11.5 
mm). This is similar to previous work that used transwells inside of 24-well plates [57]. To 
secure the membrane, an outer ring (ID x OD = 12 x 15 mm) was snapped around the inner ring 
(Figure 3A). Rings and membrane were sterilized by autoclave prior to use.  
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Figure 3. PEEK Rings. (A) Schematic of inner ring (left) and outer ring (right) (measurements 
are in inches). (B) To create a surface for cells to grow, PCTE membrane was placed over the 
inner ring. The outer ring was then “snapped” around the inner ring in order to hold the 
membrane in place. 
 
3.3 Materials 
 
3.3.1 Antibodies and Reagents 
 
Human umbilical vein endothelial cells (HUVECs) and endothelial growth media MV2 were 
purchased from PromoCell (Heidelberg, Germany). RPMI 1640 (Gibco) media and Penicillin-
Streptomycin-Glutamine (PSG) were purchased from ThermoFisher Scientific (Waltham, MA). 
Human fibronectin was purchased from Alfa Aesar (Tewksbury, MA). Type I bovine collagen 
B 
A 
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solution was purchased from Advanced BioMatrix (San Diego, CA). Human tumor necrosis 
factor (TNF-α), rhGM-CSF, rhIL-6, rhIL-4, rhIL-1β and Prostagladin E2 (PGE2) were purchased 
from PeproTech (Rocky Hill, NJ). Anti-human fluorochrome-conjugated CD31 (clone WM59), 
CD54 (clone HCD54), CD106 (clone STA), CD11a/CD18 clone (LFA-1) (clone m24), CD49d 
(VLA-4) (clone 9F10), HLA-DR (clone L243), CD1c (clone L161), CD206 (MMR, clone 15-2), 
CD83 (clone HB15e), CD86 (clone BU63), CD3 (clone UCHT1), CD25 (clone BC96) and their 
respective isotype controls, Ms IgG1 (clone MOPC-21), Ms IgG2a (clone MOPC-173) were 
purchased from BioLegend (San Diego, CA). Anti-mouse/human CD11b (clone M1/70) and its 
respective isotype, Ms IgG2b (clone MPC-11) were purchased from BioLegend. Purified anti-
human fluorochrome-conjugated CD31 (clone WM59), PE Goat anti-mouse IgG (clone 
Poly4053) secondary antibody and its isotype, purified Ms IgG1 (clone MOPC-21) were 
purchased from BioLegend. Tetanus toxoid (TT) was purchased from Sigma-Aldrich (St. Louis, 
MO). Human MCP-1 ELISA set was purchased from BD Sciences (San Diego, CA). Fetal 
bovine serum (FBS) was purchased from GE Healthcare Life Sciences (Logan, UT). ProLong 
Glass Antifade Mountant with NucBlue Stain with DAPI was purchased from Invitrogen 
(Carlsbad, CA). 
3.4 Cell Culture 
 
3.4.1 HUVECs 
 
Membrane rings were coated with a fibronectin (25 µg/mL) and type 1 collagen (3.1 mg/mL) 
solution for a minimum of 2 h. Media was then added 24 h prior to seeding with cells. HUVECs 
were cultured in a T-75 flask pretreated with fibronectin for 72 h to reach confluency prior to 
seeding onto membrane rings. After 72 h, cells were detached with trypsin/EDTA and seeded 
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onto membrane rings at 100,000 cells/cm2. Only passages 2-5 were used. ECs were cultured for 
72 h in a 24 well cell culture plate (1.9 cm2, Greiner BioOne, Monroe, NC) to allow for cells to 
reach confluency on rings. After 72 h, rings were placed in the well inserts in the bioreactor. 
Using Masterflex L/S pump, flow rate was set to 0.4 mL/min for 72 h. To test for EC response to 
inflammation, TNF-α (10 ng/mL) was added after 24 h.  
3.4.2 Monocytes 
 
Human peripheral blood mononuclear cells (PBMCs) were isolated by the Ficoll-Plague density 
separation method (GE Healthcare; Pittsburg, PA) from blood of healthy donors obtained from 
Oklahoma Blood Institute (OBI, Oklahoma City, OK). Autologous plasma was also obtained 
from OBI. CD14+ monocytes were isolated from PBMCs using CD14 MicroBeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany). Monocytes were frozen in plasma until use. For 
migration study, monocytes were stained with carboxyfluorescein succinimidyl ester (CFSE, 
Invitrogen) prior to addition to bioreactor. Monocyte concentration (500,000 cells/mL) was 
based on physiological concentration. Monocytes were added to each well after 24 h of culturing 
HUVECs with or without TNF-α under flow conditions. Monocytes were cultured under 0.4 
mL/min flow rate for 48 h based on previous work [5].  
3.5 Characterization of HUVECs 
 
3.5.1 Morphology 
 
Morphology of HUVECs on membrane rings was determined by microscopy using Nikon 
TE2000 fluorescent microscope. Rings were removed from plate bioreactor and placed in a 24-
well tissue culture plate. Cells were rinsed with PBS and then fixed with 4% paraformaldehyde. 
Cells were then blocked with a 5% FBS in PBS solution (v/v) to prevent nonspecific antibonding 
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binding. Purified CD31 and its respective isotype were prepared in FBS/PBS solution added to 
each ring to label cellular membrane. PE goat secondary antibody in FBS/PBS was added to 
increase fluorescent signal. Membranes were then cut out of PEEK rings, placed on glass slides 
and counterstained with DAPI to label nuclei of HUVECs.  
3.5.2 CAM Expression and MCP-1 Release 
 
Expression of CD31 (PECAM-1), CD54 (ICAM-1) and CD106 (VCAM-1) by ECs was 
determined by flow cytometry using BD Accuri C6 flow cytometer. Trypsinized cells were 
collected and stained with anti-CD31, anti-CD54 and anti-CD106 or their isotype controls (45 
min, 4oC) following manufactures protocol. Viability of cells was determined by use of Zombie 
Green fixable viability kit (BioLegend). To determine secretion amount of monocyte 
chemotactic protein (MCP)-1, culture supernatants were collected and stored at -80oC until 
analysis. Supernatants were analyzed with commercial enzyme-linked immunosorbent assay 
(ELISA) following manufactures protocol (BD Biosciences, San Diego, CA).  
3.6 Characterization of Monocytes 
 
3.6.1 Migration 
 
CFSE stained (0.5 µM) monocytes amounts were calculated based on fluorescent intensity using 
fluorescent plate reader. CFSE is cell permeant and once inside the cell, the acetate groups are 
removed by intracellular esterases thus causing the CFSE to strongly bind to amino groups in the 
cell. Manufactures staining protocol was followed.  A standard curve was generated by preparing 
known monocyte concentrations in media in a 96-well plate in parallel with monocytes in 
bioreactor. 48 h after monocyte addition, media was collected above and below each ring, 
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centrifuged and resuspended in media in a 96-well plate. For monocytes located on the 
endothelial layer, monocytes were detached using trypsin/EDTA, centrifuged and resuspended in 
media in a 96-well plate. The equation from the standard curve was then used to calculate 
monocytes at each location.  
3.6.2 Surface Marker Expression 
 
Expression of CD11b, CD11a/CD18 (LFA) and CD49d (VLA-4) by monocytes was determined 
by flow cytometry. Media was collected from above and below the endothelium layer. For 
monocytes attached to HUVEC layer, trypsin/EDTA was used to lift monocytes off 
polycarbonate membrane. All samples were centrifuged and stained with anti-CD11b, anti-LFA, 
and anti-VLA-4 or their isotype controls following manufactures protocol. Marker expression 
after culture was compared to before at each location and with or without TNF-α.   
 
3.7 Characterization of Monocyte-Derived DCs 
 
3.7.1 Morphology 
 
Morphology of DCs generated in the bioreactor system was determined by microscopy. After 48 
h in culture, cells were collected from all locations in bioreactor and resuspended in DPBS. 
Samples were then stained by Wright-Geisma. Samples were analyzed under light microscopy 
for DC characteristics of both statically grown and bioreactor generated DCs. DCs were 
compared to monocytes and between their immature and mature state to observe any 
morphological changes.  
 
 
23 
 
3.7.2 Phenotypic Marker Expression 
 
Expression of HLA-DR, CD1c and CD206 (MMR) was determined by flow cytometry. 
Collection of was done as stated previously in 3.5.2. All wells were pooled, centrifuged and 
stained with anti-HLA-DR, anti-CD1c, and anti-CD206 or their isotype controls following 
manufactures protocol. CFSE+HLA-DR+ cells were analyzed for expression of CD1c and 
CD206. Number of DCs were identified by expression level of either CD1c, CD206 or both, as 
these are common DC markers. Those showing negatively for CD1c and CD206 were considered 
to still be monocytes. Marker expression was compared between location in the bioreactor.  
3.7.3 Functionality 
 
MLR was used to determine the functionality of DCs generated in the bioreactor system. Cells 
were collected from each well in the bioreactor, pooled and distributed between 6 wells in a 96-
well round bottom plate in RPMI-1640 containing 250 ng/mL GM-CSF, 100 ng/mL IL-4, 1% 
PSG, 10% FBS and 30% autologous plasma. DCs were first loaded by adding TT (10 ug/mL) to 
half of the wells to test DCs ability to take up and process antigens. Loading DCs prior to 
maturing has shown to promote better interaction and proliferation of T-cells [60]. After 24 h 
incubation with TT, DCs were pushed toward maturation by adding 10 ng/mL of TNF-α, 10 
ng/mL of IL-1β, 1 µg/mL of PGE2, and 100 U/mL of IL-6 and incubated an additional 24 h prior 
to MLR. To act as a control, DCs were generated statically by culturing monocytes for 5 days in 
RPMI-1640 medium containing 1% PSG, 10% FBS, 30% autologous plasma, 250 ng/mL GM-
CSF and 100 ng/mL IL-4. Half of media was changed every 48 h. Loading and maturation for 
static cultured DCs was the same as bioreactor DCs. DCs were analyzed for expression of CD83, 
CD86 and HLA-DR by flow cytometry after 48 h in bioreactor to determine maturity of cells and 
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amount of DCs present. DCs were again analyzed after maturation cytokines were added to see if 
DCs had matured before beginning MLR. 
T-cells were isolated from the same donor as monocytes and stored in plasma until use. CD3 
Microbeads (Miltenyi Biotec) were used to positively select for T-cells. T-cells were stained with 
CFSE (1 µM) following manufactures protocol prior to addition with DCs to examine 
proliferation. DCs and T-cells were mixed at a ratio of 1:10 and incubated for seven days, 
changing half of the media every other day. Proliferation of T-cells by CFSE decay along with 
markers CD3 and CD25 were analyzed by flow cytometry after 7 days in culture with DCs. To 
serve as a control, CFSE labeled and unlabeled T-cells were incubated without DCs in parallel.  
 
3.8 Statistical Analysis 
 
Experimental results are expressed as means ± SD of three samples. For studies using cells 
isolated from human peripheral blood mononuclear cells, experimental results are expressed as 
means ± SD of three donors.  Student t-test was used for pairwise comparison of groups or 
between two groups, respectively. A value of p < 0.05 was considered significant.  
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Chapter IV 
 
Results and Discussion 
 
4.1 Characterization of HUVECs 
 
4.1.1 Morphology  
 
The first objective we wanted to ensure was that the bioreactor provided a suitable environment 
for cells to be cultured in. All wells during each experimental run were cultured in the same 
manner for with and without TNF-α. Figure 4 shows morphology of HUVECs on the membrane 
surface. Without TNF-α being added to the system (Figures 4A and 4B), HUVECs showed a 
tight, compact network and were confluent across the entire membrane. By maintaining this 
compact network, HUVECs worked to line the PCTE membrane to create a vascular boundary 
between the upper and lower chamber in the bioreactor. These tight junctions help to regulate 
what passes through the endothelium, only allowing nutrients or important leukocytes access to 
area beneath the endothelium. Cells after culture in the bioreactor also appeared wider than those 
in a static control.  
When TNF-α was introduced to the system for 48 h, ECs lost their compact network and became 
more elongated. ECs also became more spread out and had larger membranes than without TNF-
α. Fewer cells appeared on the PCTE membrane which suggest that when TNF-α is added as an 
inflammatory stimulate, proliferation of ECs decreases [61]. Looser junctions between cell 
membranes though does allow for more traffic to pass through like macromolecules and cells 
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[62]. It also allows in conjunction with loose junctions for leukocytes to attach or pass through 
easier, simulating the beginning of the immune response similar to in vivo [63]. This 
morphological change also is consistent with a previous report where EC aspect ratio increased 
to around 10 [64].  
 
 
Figure 4. TNF-α treatment changes the morphology of HUVEC’s in the plate bioreactor. 
HUVECs were cultured in the bioreactor for total 72 h. Morphology of HUVECs were examined 
by staining the cells with anti-PECAM-1 counterstained with DAPI followed by fluorescence 
microscopy (200x). A and B, cells without TNF-α, C and D, cells with TNF-α added for the final 
48 h. A and C, DAPI-stained HUVECs; B and D, HUVECs stained with anti-PECAM antibody 
counterstained with DAPI. Shown is a representative of the combination of 3 independent 
experiments. 
B A 
C D 
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An interesting result based on morphology is that cells did not align to the direction of flow as 
others have previously reported [65, 66]. One reason could be due to the system producing 
disturbed flow, which is where flow is nonuniform and has irregular distribution of low shear 
stress [67]. This is due to low shear stress and flow path inside our bioreactor can be confirmed 
by CFD modeling of our system (data not shown). Disturbed flow though is not uncommon in 
the body and is quite present in veins and arteries at branch points [67, 68]. The results are more 
closely aligned to previous studies with disturbed flow but did not have any negative on 
HUVECs effects because of it [62, 68]. 
 
 
4.1.2 CAM Expression and MCP-1 Release 
 
To see HUVEC’s response to flow in the bioreactor, we looked at PECAM-1, ICAM-1,VCAM-1 
expression along with MCP-1 release. Viability with and without TNF-α were 78% and 82%, 
respectively. Viable ECs showed high expression (>97%) of ICAM-1 and PECAM-1 after 72 h 
in bioreactor with and without TNF-α (Figure 5). PECAM-1 is a common marker for ECs and 
should be expressed on all HUVECs. No alterations in PECAM-1 expression indicates the 
system does not affect typical HUVEC phenotype. High expression of ICAM-1 has been thought 
to be due to the change in shear stress the ECs are experiencing compared to if they were 
statically cultured. ICAM-1 median fluorescent intensity (MFI) increased compared to static ECs 
(data not shown), indicating cells in the bioreactor are responding similar to previous reports  
[65, 69, 70]. With TNF-α, ICAM-1 has been shown to influence the contractions ECs are 
experiencing, causing them to widen and even increase in height [63, 65]. Widening of 
HUVECS can be seen by the morphological change of HUVECs discussed in 4.1.1.  
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VCAM-1 is an inflammatory response marker and is upregulated when ECs are stimulated with 
certain cytokines such as TNF-α [65, 71]. VCAM-1 expression without TNF-α was almost none 
(5.5%), indicating that HUVECs are not experiencing any sort of inflammatory condition. Shear 
stress experienced by HUVECs due to flow should also have no effect on the expression of 
VCAM-1 on ECs [63, 65]. When HUVEC’s were activated with TNF-α, VCAM-1 expression on 
viable ECs was significantly upregulated 37% compared to ECs that were not activated. VCAM-
1 plays a role in leukocyte regulation during an inflammatory response. Leukocytes bind to the 
α5β1 on ECs and VCAM-1 was shown to increase its activation, leading to more cells flowing 
over the top of the endothelium binding to the EC layer [71]. HUVEC upregulation of VCAM-1 
suggests that ECs in bioreactor respond accordingly to inflammatory stimuli.  
Similar to VCAM-1, ECs that are stimulated with certain cytokines secrete more MCP-1 than if 
they were unstimulated. MCP-1 is secreted to recruit monocytes to sites of inflammation [72, 
73]. After the addition of TNF-α, concentration of MCP-1 significantly increased 6x than 
without the inflammatory stimulus (Figure 6). In response to MCP-1, more monocytes 
infiltrating through the endothelium had been shown in response to increased MCP-1 release by 
HUVECs [73]. Along with recruitment and migration of monocytes to the endothelium, MCP-1 
has been shown to also signal angiogenesis to begin [74, 75]. Unlike a previous study, disturbed 
flow did not play a role in upregulating MCP-1 [76]. This helps for us to assume that bioreactor 
itself isn’t affecting the HUVECs in a way to behave abnormally even with disturbed flow taking 
place.   
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Figure 5. TNF-α selectively alters CAM expression in HUVECs. HUVECs were cultured in the 
plate bioreactor for total 72 h, and TNF-α was added for the final 48 h. Cells were stained with 
monoclonal antibodies against CAMs and analyzed by flow cytometry. Data are represented as 
mean ± SD; n=3. * indicates significantly different (p < 0.05) between with and without TNF-α. 
 
 
Figure 6. TNF-α significantly increases release of MCP-1 by HUVECs. Media was collected 
after a total of 72 h for both with and without TNF-α and stored at -80oC until analyzed by 
ELISA. Data are represented as a mean ± SD; n=3. * indicates significantly different (p < 0.05) 
between with and without TNF-α.  
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4.2 Characterization of Monocytes 
 
4.2.1 Migration  
 
Monocytes were stained with CFSE to track their location in the bioreactor after being cultured 
under flow conditions for 48 h. With an unstimulated endothelium, monocytes were relatively 
the same above and below the endothelium, as shown in Figure 7. Tight junctions created by 
HUVECs reduced the ability of monocytes to easily pass through the endothelium. Thus, 
monocytes must first adhere to the endothelium, crawl to a junction and perform diapedesis in 
order to migrate beneath the HUVEC monolayer. Monocytes beneath the endothelium simulates 
their infiltration into tissues. When the HUVEC layer was stimulated for 24 h prior to addition of 
monocytes, monocytes located above the endothelium significantly decreased (49% to 30%), 
causing more monocytes to migrate through the endothelium (38% to 61%). Without as compact 
network of HUVECs, monocytes were able to perform diapedesis much easier. The addition of 
flow as well could have driven more monocytes to migrate through as well [77].  
Monocytes attached to the endothelium remained relatively the same regardless of if TNF-α was 
added to stimulate HUVECs. A small to little change to attachment of monocytes to the 
endothelium could be due to the limited attachment sites presented by HUVECs. TNF-α 
stimulated endothelium had been shown to increase monocyte attachment, but that was not the 
case for monocytes in the bioreactor[78].  
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Figure 7. TNF-α affects the localization of monocytes in the plate bioreactor. CFSE-stained 
monocytes were added to the HUVEC monolayers in the bioreactor and collected after 48 h. 
Monocytes were lifted from the membranes, as well as collected from the chambers above and 
below the membranes. Number of monocytes were calculated from a standard curve based on the 
fluorescent intensities of known monocyte numbers. Data are represented as mean ± SD; n=3. * 
indicates p < 0.05 between with and without TNF-α.   
 
4.2.2 Surface Markers 
 
Monocyte markers CD11b, VLA-4 and LFA were observed as they have been linked to playing a 
role in monocyte migration [79-81]. Figures 8A-C shows the results of each marker and its 
expression on monocytes after 48 in culture compared to before addition to bioreactor. 
Monocytes that were observed were CFSE positive. When the endothelium was not stimulated 
with TNF-α, CD11b was relatively unchanged in all three locations in the bioreactor. LFA 
expression increased for monocytes that migrated through the endothelium indicating LFA on 
monocytes is possibly part of their migration process, which is consistent with a previous report 
[82]. VLA-4 was downregulated in all locations. Immature DCs have been shown to have low 
32 
 
levels of VLA-4 [83]. The recovered cells not only could be monocytes, but some could be DCs 
or macrophages. 
When HUVECs were stimulated with TNF-α, all phenotypic markers decreased in expression. 
VLA-4 expression at all locations decreased significantly in expression. This leads us to believe 
that monocytes are less likely to use VLA-4 during migration in the bioreactor. This is 
contradictory to previous reports saying VLA-4 is heavily involved in migration of monocytes 
[84]. Also, decreased expression in VLA-4 could be because cells labeled with CFSE were not 
monocytes but possibly macrophages or DCs. CD11b expression for monocytes attached to the 
endothelium and below were significantly downregulated. CD11b has been shown to be 
downregulated or nonexistent on DCs generated from monocytes [2]. This leads us to believe 
that when HUVECs are inflamed due to addition of TNF-α, they could be differentiating into 
DCs [85, 86].  
By not labeling for CD16, our system could contain any of the three types of monocytes that 
have been described earlier. Both CD11b and LFA-1 are part of the β2 integrin family and have 
previously been shown to play a role in adhesion and migration of leukocytes. High expression 
of CD11b indicates that monocytes in the bioreactor are more than likely classical or 
intermediate monocytes rather than non-classical [87]. CD11b is thought to be involved for firm 
adhesion of monocytes to endothelium due to its interaction with ICAM-1 [88]. That does not 
seem to be the case, as CD11b varies only slightly on unstimulated endothelium. For monocytes 
attached to the activated endothelium, a high downregulation in expression of CD11b could be 
due to monocytes shifting away from monocyte lineage [89].  
LFA-1 has previously been shown to be a factor in migration of monocyte by working with the 
ICAM-1 ligand on endothelial cells [90]. With little to no decrease in expression of LFA-1, it 
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may show that adhesion to inflamed tissue by monocytes may actually not use LFA-1 like a 
previous report suggest [91]. With most previous studies, they looked at migration of monocytes 
in static systems or for less than 24 h [82, 84]. By adding 24 or more h to the time than previous 
researchers performed, it could play a role in changing the phenotypes or migration receptors 
used by monocytes. All this possibly then means that other receptors on monocytes that were not 
looked at could play a bigger role in migration instead of the ones analyzed in this study for 
monocytes that are in circulation for a longer period of time.   
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Figure 8. Monocytes downregulate expression of common phenotypic migration markers 
CD11b and VLA-4 after 48 h under flow conditions with TNF-α. Monocytes were collected at 
each location and flow cytometry was used to analyze marker expression (A) above (B) attached 
(C) below endothelium. When compared to with and without TNF-α, VLA-4 expression was 
A 
B 
C 
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significantly downregulated on monocytes at all locations. LFA-1 expression was slightly 
upregulated under normal conditions for monocytes that migrated through endothelium. Under 
inflammatory conditions, expression of CD11b was downregulated at all three locations. Results 
are represented as difference between before and after culture in bioreactor. Data are represented 
as mean ± SD; n=3. * indicates significantly different (p < 0.05) between with and without TNF-
α. 
 
4.3 Characterization of Monocyte-Derived DCs 
 
4.3.1 Morphology 
 
Figure 9 shows morphology of monocyte derived DCs after 48 h in bioreactor (E-H) and 
statically cultured (A-D). DCs cultured in the bioreactor had no morphological changes 
compared to those grown in static culture. Nuclei of DCs were rounded, indicating that 
differentiation had taken place from monocytes as precursor cells have more of a horseshoe 
shape nuclei. Both also were irregular in cytoplasmic shape, which is typical of DC morphology 
[92]. This implies that the bioreactor had no ill-effects on DC morphology compared to DCs 
generated in a 2D static system with cytokines. DCs generated from the bioreactor were almost 
2X larger than monocytes. After addition of TT and maturation cytokines, DCs grew dendrites 
on their surface of the cytoplasm (B, D, F, H), which is a typical indication that maturation has 
taken place [92]. Further analysis by flow cytometry confirmed that cells were DCs at both 
immature and mature states. Cytoplasm of mature DCs was also darker in color compared to 
those in an immature state for bioreactor DCs due to more granules being present.  
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Figure 9. Vascular system has no effect on morphology of monocyte derived DCs. Cells were 
stained by Wright-Giesma and analyzed with light microscope. (A) & (C) DCs generated in 
static culture with media containing GM-CSF and IL-4 did not vary in morphology compared to 
DCs generated after 48 h in vascular bioreactor (E) & (G) After addition of maturation cytokines 
for 24 h, DCs generated statically (B & D) and bioreactor (F & H) developed dendrites on the 
surface. Arrows indicate DCs. A, B, E and F were taken at 200X. C, D, G and H were taken at 
400X.  
A 
B 
E 
F 
C G 
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4.3.2 Phenotypic Marker Expression 
 
CFSE labeled monocytes were used to gate for differentiated DCs. They were further identified 
by only looking at HLA-DR+ cells, which is only expressed on antigen presenting cells (APC) 
and eliminated HUVECs from analysis. If cells were expressing CD1c, CD206 or both, they 
were considered to be DCs. After 48 h, almost 50% of recovered DCs were located below the 
endothelium layer (Figure 10). Of those DCs located below the endothelium, there were roughly 
equal amounts of DCs expressing CD1c and CD206 (Figure 11). One possible reason for more 
DCs to migrate through could be due to flow, which could drive DCs to migrate rather than 
remain above or attached. The largest difference in DC population was for DCs attached to the 
endothelium, where 81% of recovered DCs were expressing CD206 while only 19% expressed 
CD1c. This could imply that CD206 could play a role in DCs attachment to HUVEC monolayer. 
Above the endothelium had 37.5% of the DC population and majority of them being CD206+ 
(62.5%). DCs have been shown to reverse migrate and there is a possibility that CD206 DCs 
favor reverse migration over CD1c. A high expression was seen on recovered cells for CD14, 
which is common on monocytes but is typically shed when they differentiate into DCs. When 
looking at CD14 expression on recovered cells, there were two peaks of expression (data not 
shown) which indicates that there are two different populations of cells. The peak with a higher 
fluorescent is presumably still monocytes. The peak that had a lower fluorescent were assumed 
to be the generated DCs, that had lost the their CD14 expression. Immature DCs had been shown 
to still express some CD14 to some capacity [34, 35, 93].  
Blood monocyte derived DCs do not have one distinct marker to label them. Both CD206 and 
CD1c had been shown to be present on blood monocyte derived DCs [33, 94, 95]. With different 
38 
 
expression and subsets of DCs, each are unique in their role. CD1c DCs produce more IL-8, 
which is crucial as a chemoattractant stimulus for other immune response cells [94]. CD1c DCs 
have also been shown to be the strongest T-cell stimulator when compared to 4 other subsets of 
DCs from monocytes in MLR experiments [86]. CD206 is important in the antigen uptake 
performed by DCs [96]. These antigens are later presented to help stimulate T-cell response so 
they can proliferate and activate other immune response cells.  
 
Figure 10. Monocyte derived DCs favor remaining below endothelium after 48 h in bioreactor. 
Cells were collected from all three locations, stained with anti-CD1c, anti-HLA-DR and anti-
CD206 and analyzed by flow cytometry. DCs are CFSE+HLA-DR+ and either CD1c, CD206 or 
both at that specific location. Data are represented as mean percentage of DC population; n=3.  
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Figure 11. DCs generated in bioreactor system from monocytes expressed more CD206 than 
CD1c. Cells were collected from all three locations, stained and analyzed for common monocyte 
derived DC markers. Percentages are of recovered DCs at that specific location. DCs that were 
above and attached to endothelium had higher expression of CD206 than CD1c. Data are 
represented as mean percentage; n=3.  
 
4.3.3 Functionality 
DCs were collected out of the bioreactor and analyzed first for maturation state. For all analysis, 
cells were gated for HLA-DR prior to any observation of antibodies. DCs collected out of the 
bioreactor had a viability of 88.2%, which was comparable to those grown statically (95.9%). 
Viable bioreactor DCs and statically generated DCs, indicated by their expression of CD86 (89.9 
and 88.5%, respectively), both expressed low levels of CD83 before addition of maturation 
cytokines (Figure 12). After maturation cytokine addition, bioreactor and statically generated 
DCs significantly upregulated their expression of CD83 (72.0 and 84.9%, respectively). CD86 
for both sets had also a higher fluorescent intensity and total amount of cells expressing the 
marker (>99%) when compared to monocytes and immature DCs, further indicating that 
maturation of DCs had taken place.   
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Figure 12. CD83 expression upregulated on DCs after addition of cytokines, an indication of DC 
maturation. Cells were collected after 2 days in bioreactor or 7 days in static culture. TT was 
added for 24 h followed by addition of maturation cytokines for 24 h. Results show CD83 and 
CD86 expression before TT and after addition of maturation cytokines. Data are represented by 
mean ± SD; n=4. Three separate donors are represented. * indicates significantly different (p < 
0.05) between before and after maturation cytokine addition.  
 
T-cell proliferation was measured by looking at CFSE decay on CD3+CD25+ T-cells. CD3 is 
expressed on all T-cells and is required for antigen recognition [97]. CD25 is upregulated when 
T-cells have been activated [98]. During proliferation, CFSE is roughly halved every time a cell 
divides. CFSE has been used quite extensively in T-cell proliferation studies due to its slow 
release from inside the cell [99]. T-cells analyzed for proliferation were all CD3+ (>99%, data 
not shown). 
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Table 1. Expression of CD25 after MLR for 7 days. Data are represented as mean ± SD; n=4. 
Three separate donors are represented. 
 
 
 
 
 
T-cells with bioreactor DCs had both lower CD25 expression when compared to static cultures 
under the same conditions. This could possibly be due to DCs dying, thus eliminating a 
stimulation source. Previous work has shown that T-cells downregulate CD25 after stimulation 
occurs [100]. T-cells with DCs from the bioreactor loaded with TT expressed roughly 12% more 
CD25 than T-cells mixed with DCs without any antigen (Table 1).   
 
Figure 13. T-cells with DCs preloaded with TT proliferate more than T-cells mixed with 
unloaded DCs. DCs generated in the bioreactor loaded with TT (blue) induced more proliferation 
of T-cells than bioreactor DCs without TT (green). The same can be said for DCs from static 
cultures (with TT = red; without TT = orange). A peak shifted farther left means cells divided 
since CFSE decay is believed to half every time a cell doubles. Isotype control from Day 0 of T-
cells is shown in black. Data are from four experiments; three separate donors are represented.  
 
Expression of CD25 (%) 
Bioreactor with TT 52.2 ± 25.4 
Bioreactor without TT 40.2 ± 19.4 
Static with TT 75.4 ± 7.6 
Static without TT 60.4 ± 16.5 
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Even though T-cells had lower expression of CD25 when mixed with bioreactor DCs, bioreactor 
DCs were able to promote better proliferation of activated T-cells (CFSE+CD3+CD25+) than 
those generated statically. As shown in Figure 13, activated T-cells mixed with DCs loaded with 
TT were better stimulators for proliferation than those without. Peaks shifted farther to the left 
indicate more proliferation had occurred since CFSE concentration roughly halves every time a 
cell divides. Table 2 shows a summary of median fluorescent intensity (MFI) of CFSE of T-cells 
mixed with DCs. By being able to proliferate more, this in turn promotes an organized and more 
rapid immune response to stop an infection or disease.  
 
Table 2. Median fluorescent intensity (MFI) of CFSE by activated T-cells after MLR for 7 days. 
Data are represented as mean ± SD; n=4. Three separate donors are represented. 
 
 
 
 
  
CFSE MFI 
Bioreactor with TT 2638 ± 2438 
Bioreactor without TT 2976 ± 2721 
Static with TT 9397 ± 15600 
Static without TT 12843 ± 13046 
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Chapter V 
 
Conclusion 
 
We have developed and characterized a novel bioreactor system that generates functional DCs. 
The novel bioreactor was able to allow for proper growth and proliferation of ECs on a 
polycarbonate membrane under flow. Without TNF-α, ECs formed a tight, compact network. 
When TNF-α was added to simulate inflammation, ECs became elongated and more spread out 
to possibly allow for more leukocytes to migrate through the endothelium [66]. ECs also 
significantly increased their VCAM-1 expression and release of MCP-1, both of which have 
been shown to be common inflammatory responses [71, 72].  
To look at migration tendencies of monocytes when added to the bioreactor, monocytes were 
labeled with CFSE to track location. When endothelium was unstimulated, monocytes above and 
below the HUVEC monolayer were relatively equal in distribution. When HUVECs were under 
an inflammatory condition, more monocytes migrated below the endothelium; simulating 
monocytes entering an inflamed tissue to begin an inflammatory response. This is consistent with 
Shukla who found that more leukocytes tend to migrate through stimulated endothelium than an 
unstimulated one [6]. All migration markers on monocytes were downregulated when ECs were 
pretreated with TNF-α. CD11b’s significant downregulation on monocytes when attached or 
below endothelium could be due to them shifting away from lineage [89]. The significant 
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downregulation of VLA-4 and CD11b could also be due to monocytes differentiating into DCs 
where both have been shown to be lost on DCs [2, 83].  
DCs in the bioreactor were typical in morphology when compared to statically cultured DCs 
[92]. A significant increase in CD83 expression on DCs indicates they had matured after the 
addition of maturation cytokines prior to the MLR [34, 35]. T-cells mixed with DCs from the 
bioreactor had lower expression of the activation marker CD25. This could be due to DCs dying; 
thus eliminating T-cell stimulation and starting a downregulation of CD25 expression [100]. DCs 
with TT had more interaction with T-cells as indicated by the expression of activation marker 
CD25 on T-cells. For T-cells mixed with bioreactor DCs loaded with TT, DCs had better 
interaction and stimulation for proliferation of T-cells than without TT. This indicates DCs from 
the bioreactor are behaving similar to previous studies and have the capability to properly take 
up, process and present the antigen for T-cells [35, 101]. Activated T-cells proliferated more 
when mixed with bioreactor DCs than their static counterparts, thus indicating better 
functionality [102]. Overall, DCs generated in the novel bioreactor were more functional based 
on ability to stimulate the proliferation of activated T-cells than traditionally generated static 
DCs.    
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Chapter VI 
 
Future Work 
 
Optimize the bioreactor by adjusting the height at which cells lie beneath the inlet to create 
laminar flow over the cells. This could result in better mechanical stimuli for cells to be more 
viable and have a more typical morphology under flow conditions. Disturbed flow in the 
bioreactor could be causing a high monocyte death or pushing cells to apoptosis. Eliminating 
disturbed flow could result in better viability and functionality of DCs that are recovered, 
resulting in a higher yield of DCs after culture in the bioreactor. Further study into the 
functionality of the DCs analyzing more surface markers such as CD1a, CD64, CD80 and CCR7 
should be done as well. In this study, we did not look into if or how many macrophages were 
being generated since monocytes can differentiate into either DCs or macrophages. Looking into 
that could give us a more exact idea on if our system is really favoring DC generation. If not, 
then further optimizing of the system to favor DCs could be studied. 
Studying other designs, such as a tubular form of a bioreactor, to better simulate the vascular 
network. Initial studies have begun to do so, but creating a vascular scaffold has proven to be 
quite difficult. This would give a better representation of in vivo conditions and could prove to 
generate more functional DCs than those generated by the plate bioreactor. Using CFD to model 
it, we can optimize the system to produce the most DCs. At the end, we could compare the plate 
to tubular reactor to see if it affects the cells any differently.  
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Appendix 
 
Appendix A: Tubular Reactor 
A tubular bioreactor was created but was not tested during this project. Figures A1 shows the 
bioreactor. The material of for the reactor chamber is the same as that for the plate bioreactor. 
Different variations to create a tubular mold had been tried but were unsuccessful. Right now, 
developing a sterilization technique for a collagen/chitosan solution would be the best method. A 
stainless steel mold has been fabricated. After adding collagen/chitosan solution into the mold, it 
is frozen at 4oC for 2 h. After 2 h, the center rod is removed and lyophilized for 24 h. After 24, 
the scaffold is removed from the outer mold and the rod is reinserted into the annular of the 
scaffold to maintain inner diameter which is then placed a 1% TPP solution for 24 to crosslink. 
After 24 h, the scaffold is washed 5X with Ultrapure water and refrozen at 4oC for 2 h. It is again 
placed back on the freeze dryer to be lyophilized for 24 h.  
 
Figure 1A. Tubular bioreactor.  
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The tubular scaffold then needs to be scaffold and attempts to do have been done. By placing it 
in a 70% ethanol solution for 24 h followed by UV sterilization has seen some success but does 
not work every time.   
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